5CXZ
SYK catalytic domain complexed with naphthyridine inhibitor
5CXZ の概要
| エントリーDOI | 10.2210/pdb5cxz/pdb |
| 分子名称 | Tyrosine-protein kinase SYK, GLYCEROL, CHLORIDE ION, ... (5 entities in total) |
| 機能のキーワード | transferase/transferase inhibitor, transferase-transferase inhibitor complex |
| 由来する生物種 | Homo sapiens (Human) |
| 細胞内の位置 | Cell membrane : P43405 |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 34118.73 |
| 構造登録者 | Thoma, G.,Veenstra, S.,Strang, R.,Blanz, J.,Vangrevelinghe, E.,Berghausen, J.,Lee, C.C.,Zerwes, H.-G. (登録日: 2015-07-29, 公開日: 2015-09-16, 最終更新日: 2024-03-06) |
| 主引用文献 | Thoma, G.,Veenstra, S.,Strang, R.,Blanz, J.,Vangrevelinghe, E.,Berghausen, J.,Lee, C.C.,Zerwes, H.G. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model. Bioorg.Med.Chem.Lett., 25:4642-4647, 2015 Cited by PubMed Abstract: Design and optimization of benzo- and pyrido-thiazoles/isothiazoles are reported leading to the discovery of the potent, orally bioavailable Syk inhibitor 5, which was found to be active in a rat PK/PD model. Compound 5 showed acceptable overall kinase selectivity. However, in addition to Syk it also inhibited Aurora kinase in enzymatic and cellular settings leading to findings in the micronucleus assay. As a consequence, compound 5 was not further pursued. PubMed: 26320624DOI: 10.1016/j.bmcl.2015.08.037 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.7 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






